Old drug, new hope? bumetanide trial targets Alzheimer's
NCT ID NCT06052163
First seen Jan 15, 2026 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This Phase 2 trial tests bumetanide, a diuretic used for decades, in 40 people with early Alzheimer's. Researchers want to see if it is safe and might help slow cognitive decline. The study is double-blind and placebo-controlled, meaning neither patients nor doctors know who gets the real drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bumetanide (a diuretic, also known as Bumex)
What this could lead to
If successful, this could point toward a new, repurposed treatment to slow cognitive decline in early Alzheimer's disease.
What could go wrong
This is a small, early-phase trial focused on safety, not proof of effectiveness. Bumetanide can cause dehydration and electrolyte imbalances, especially in older adults.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.